Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Utah Medical Products, Inc.NASDAQ: UTMD

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $3.44M fell 17.5% year over year, behind the +0.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at -2.4% a year.

Context

  • Cost of revenue amounted to 48.4% of revenue in FY2025, up 7.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.5% toward the trailing-twelve-month pace of +0.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.44M-20.2% QoQ
Last fiscal yearDec 2025
$18.65M+11.2% YoY
LTMMar 2026
$17.4M+0.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year+11.2%——
3-year CAGR-2.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
18.65M USD
Year-over-year change
+11.2%
4-year CAGR
+0.7%

Cost of Revenue vs competitors

How UTMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.1% is the 6th highest of 10, against a peer median of +17.1%.
  • Cost of revenue amounts to 46.4% of revenue for UTMD, versus a peer median of 42.5%.
UTMD Competitors
Cost of Revenue for UTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$78.91M USD+141.8%+70.6%52.0%
OSUROraSure Technologies, Inc.LTM Mar 2026$66.66M USD-28.2%-34.6%59.0%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$61.59M USD-4.5%+8.6%43.3%
PREPrenetics Global LimitedLTM Mar 2026$47.41M USD+110.1%+65.9%41.7%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$22.94M USD-23.3%+12.0%30.0%
CHRSCoherus Oncology, Inc.LTM Mar 2026$18.73M USD-78.7%-36.7%40.0%
UTMDUtah Medical Products, Inc.LTM Mar 2026$17.4M USD+0.1%-2.4%46.4%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$16.67M USD+30.1%+7.4%38.5%
NYXHNyxoah S.A.LTM Mar 2026€8.43M EUR+460.5%+47.5%51.7%
PROFProfound Medical Corp.LTM Mar 2026$5.46M USD+17.1%+9.4%28.9%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$2.63M USD——426.2%
Peer median (excluding UTMD) —+17.1%+9.4%42.5%

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.05M52.28M50.22M40.9M38.52M
Cost of Revenue18.14M20.09M20.19M16.76M18.65M
Gross Profit30.92M32.2M30.04M24.14M19.88M
Gross Margin63.0%61.6%59.8%59.0%51.6%
Research & Development526K493K560K813K668K
Selling, General & Admin11.51M11.91M12.7M5.57M7.81M
Operating Expenses12.04M12.41M13.26M10.55M8.47M
Depreciation & Amortization7.28M7.08M6.37M2.77M2.95M
EBITDA26.35M27.74M24.75M19.57M17.06M
EBITDA Margin53.7%53.1%49.3%47.9%44.3%
Operating Income18.88M19.79M16.78M13.59M11.4M
Operating Margin38.5%37.9%33.4%33.2%29.6%
Interest Income166K661K03.37M0
Interest Expense00000
Other Income / Expenses181K869K3.31M3.21M2.71M
Income Before Tax19.06M20.66M20.09M16.8M14.11M
Pre-Tax Margin38.9%39.5%40.0%41.1%36.6%
Income Tax Expense4.27M4.19M3.45M2.93M2.82M
Net Income14.79M16.47M16.64M13.87M11.29M
Net Margin30.1%31.5%33.1%33.9%29.3%
EPS (Basic)4.054.534.573.963.41
EPS (Diluted)4.044.524.573.963.48
Weighted Avg Shares3.65M3.64M3.64M3.5M3.31M
Weighted Avg Shares (Diluted)3.66M3.64M3.64M3.5M3.24M

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.